Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of Oncology Clinical Trials Using Germline Genetic Data

16 Nov 2022

Abstract excerpt

Importance: The recent successes of poly-ADP ribose polymerase (PARP) inhibitors and belzutifan support germline genetic data as an exciting, accessible source for biomarkers in cancer treatment. This study hypothesizes, however, that most oncology clinical trials using germline data largely prioritize BRCA1/2 as biomarkers and PARP inhibitors as therapy. Objective: To characterize past and ongoing oncology...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Cancer Genomics and Diagnostics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36383380
DOI: 10.1001/jamanetworkopen.2022.42370

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of Oncology Clinical Trials Using Germline Genetic DataPMID 36383380Read ↗

Concurrent Germline-Somatic Alterations and Associations with Cancer Outcomes: A Systematic Review of Concurrent Data UseSemantic proximity Read ↗

Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven OncologySemantic proximity Read ↗

Umbrella review of basket trials testing a drug in tumors with actionable genetic biomarkersSemantic proximity Read ↗

High-impact trials with genetic and -omics information focus on cancer mutations, are industry-funded, and less transparent.Semantic proximity Read ↗

Cancer. Genotyping treatments.Semantic proximity Read ↗

Cancer treatment according to BRCA1 and BRCA2 mutations.Semantic proximity Read ↗

Therapeutic applications of germline testing for cancer predisposition genes in Asia in the real world.Semantic proximity Read ↗

A Precision Oncology Platform to Support Genotype-Tailored Therapy Selection.Semantic proximity Read ↗

Revolutionizing cancer drug development: Harnessing the potential of basket trials.Semantic proximity Read ↗

Clinical Trials in Precision Oncology.Semantic proximity Read ↗

Systematic pan-cancer analysis of mutation-treatment interactions using large real-world clinicogenomics data.Semantic proximity Read ↗

Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.